RxDoctor Payments Data

Marc Goldberg, MD

Ophthalmology · Sunrise, FLNPI 1588653703

Payments from drug & device makers

$1,662in general payments, 2019–2025

Across 20 payments — averaging $83.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$375
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$297
  • Amgen$261
  • Acell, Inc.$125
  • Merck$125
  • Covidien LP$103
  • plus $375 from 7 others

What the payments were for

  • Food & beverage$1,62398%
  • Gifts$392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,662 in reported general payments places this provider in the 45th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$58,744
Medicare patients
277
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine36$53,558
CombiganBrimonidine Tartrate/Timolol21$9,763
LumiganBimatoprost17$9,309
VyzultaLatanoprostene Bunod17$6,381
Travoprost18$3,278
Latanoprost236$2,971
Tobramycin-DexamethasoneTobramycin/Dexamethasone53$2,613
Prednisolone Acetate47$2,323
Ketorolac Tromethamine35$1,510
Timolol Maleate87$1,298
Dorzolamide Hcl44$781
Brimonidine Tartrate58$741
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim47$437
ErythromycinErythromycin Base31$294
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$375$6,38117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Sunrise

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →